ReNerve

ReNerve Gross Margin

The Gross Margin of ReNerve (RNV.AX) as of Nov 5, 2026 is 74.76 %. In the previous year, Gross Margin was 90.05 % — a change of -16.98% (lower).

Gross Margin

74.76 %

YoY

-16.98%

Last updated:

Gross Margin of ReNerve is 2026 74.76 % . Gross Margin of ReNerve was 2025 90.05 % . It decreases by -16.98% lower compared to the previous year.

For ReNerve, the gross margin of 74.8% is down versus 100.0% a few years ago.

The ReNerve Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2022
100.00 AUD
Jan 1, 2023
100.00 AUD
Jan 1, 2024
99.65 AUD
Jan 1, 2025
90.05 AUD
Jan 1, 2026
74.76 AUD
The ReNerve Gross Margin history
YEARGross MarginYoY
74.76 %-16.98%
90.05 %-9.63%
99.65 %-0.35%
100.00 %0.00%
100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd develops medical devices for nerve repair and soft tissue surgery, focusing on products that accelerate regeneration and prevent scarring. The company offers NervAlign Nerve Cuff, a protective wrap for repaired nerves, and NervAlign Nerve Graft, which allows surgeons to repair damaged nerves without harvesting the sural nerve. NervAlign Bionic Nerve combines polymer technology with nerve grafts to create a replacement nerve using shaped ionic polymers for distal nerve stimulation. These products target surgical procedures requiring nerve repair, with hospitals and surgical centers as primary buyers. The company's revenue comes from selling NervAlign products directly to healthcare providers involved in nerve repair surgeries. NervAlign Nerve Cuff is designed for protecting repaired nerves during surgery, while NervAlign Nerve Graft eliminates the need for patient nerve harvesting. NervAlign Bionic Nerve represents a future product line aiming to provide advanced nerve replacement solutions. The target market includes surgical teams specializing in peripheral nerve procedures and medical facilities equipped for complex soft tissue surgeries. ReNerve Ltd's products are positioned for use in peripheral nerve repair and related soft tissue surgical procedures. The NervAlign Nerve Cuff protects injured nerves during surgical repair, the NervAlign Nerve Graft enables nerve repair without patient nerve harvesting, and NervAlign Bionic Nerve aims to stimulate distal nerve ends using ionic polymers. These products are sold to hospitals and surgical centers that perform nerve repair surgeries, with the company focusing on accelerating tissue regeneration and reducing complications. ReNerve is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReNerve stock

Gross Margin of ReNerve is 74.76 % in 2026.

Gross Margin of ReNerve changed from 90.05 % to 74.76 %, representing a -16.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin ReNerve since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's ReNerve with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — ReNerve

All Key Metrics — ReNerve